Background/Objectives: Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes in patients with diabetes, heart failure, and chronic kidney disease. Their association with perioperative outcomes after major cardiac procedures remains uncertain. Methods: In this retrospective cohort study using the TriNetX U.S. Collaborative Network, adults (≥18 years) undergoing cardiac procedures were identified. Patients with documented SGLT2 inhibitor use within 1 year before the index procedure were compared with non-users. Risk ratios (RR), risk differences, Kaplan–Meier survival curves, and Cox models were used for analysis. Results: Of 150,724 patients identified, 7526 propensity score-matched pairs were analyzed. The matched cohorts had a mean age of 65.8 ± 10.6 years and were predominantly male (70.5% male, 29.5% female). Preoperative SGLT2 inhibitor use was associated with significantly lower all-cause mortality at 30 days (1.3% vs. 2.3%; RR 0.566 [95% CI 0.443–0.722], p < 0.001), 90 days (2.2% vs. 3.4%; RR 0.643, p < 0.001), and 1 year (3.8% vs. 5.8%; RR 0.657, p < 0.001). MACE rates were similar between groups at all time points. Acute kidney injury at 30 days was lower with SGLT2 inhibitors (15.4% vs. 17.7%; RR 0.870, p < 0.001), whereas hospital admission rates were higher (76.4% vs. 68.7%; RR 1.111 [95% CI 1.089–1.133], p < 0.001). These associations were consistent in diabetes-only and obesity-only subgroups and in a 30-day landmark sensitivity analysis. Conclusions: In this large, contemporary, multi-institutional propensity score-matched cohort, preoperative SGLT2 inhibitor use was associated with reduced all-cause mortality and acute kidney injury after major cardiac procedures. These real-world findings support the conduct of dedicated randomized trials evaluating perioperative SGLT2 inhibitor therapy.
Introduction: Atrial fibrillation (AF) is highly prevalent in heart failure (HF) and is linked to increased mortality and hospitalization in both preserved (HFpEF) and reduced ejection fraction (HFrEF). Catheter ablation (CA) has emerged as an effective rhythm-control strategy beyond medical therapy (MT), but phenotype-specific differences remain unclear. We compared the efficacy and safety of CA versus MT in AF with HFpEF or HFrEF. Methods: PubMed, Embase, Scopus, and Cochrane databases were searched through December 2025. Random-effects meta-analyses were conducted in R (version 4.5.3), reporting risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). Results: Fifteen studies involving 27,130 patients (CA: 13,579; MT: 13,551) were included. Catheter ablation significantly reduced overall all-cause mortality (RR 0.44), with a significant benefit in HFpEF (RR 0.44), whereas the reduction in HFrEF did not reach statistical significance (RR 0.53, 95% CI 0.21–1.38). Cardiovascular mortality and cardiovascular hospitalization were also reduced overall, without significant differences between HF phenotypes. Stroke and atrial arrhythmia recurrence were not significantly reduced in the primary analyses, and favorable findings observed in sensitivity analyses were considered exploratory . Catheter ablation significantly improved LVEF in HFrEF but not in HFpEF, while effects on exercise capacity and biomarkers varied across outcomes and phenotypes. Adverse events were comparable between treatment strategies. Conclusion: Catheter ablation was associated with favorable clinical outcomes compared with medical therapy in AF with HF; however, the magnitude and statistical certainty of benefit varied across heart failure phenotypes and outcomes.
Background: Peritoneal and omental metastasis from prostate adenocarcinoma is rare and usually occurs in the setting of widespread disease. Isolated peritoneal involvement without skeletal or nodal disease is uncommon, and the mechanism of spread is not well understood. Case presentation: A 64-year-old man presented with lower urinary tract symptoms and was diagnosed with high-risk prostate adenocarcinoma (Gleason 4 + 5=9, WHO Grade Group 5) after transurethral resection of the prostate (TURP); post-operative prostate-specific antigen (PSA) was 7.8 ng/mL, and the pre-operative work-up was not available. Staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) showed locally invasive disease extending into the seminal vesicles and bladder base, without nodal or distant metastasis. He was treated with hormonal therapy and external beam radiotherapy, achieving a PSA nadir of 0.35 ng/mL. Despite a subsequent rise in PSA, a surveillance PSMA PET/CT was negative for recurrence. PSA continued to rise progressively, reaching 59.17 ng/mL, with new lower urinary tract symptoms. Repeat PSMA PET/CT showed ascites and diffuse PSMA-avid omental caking with peritoneal fat stranding, without local recurrence, lymphadenopathy, or osseous metastasis. Image-guided tru-cut biopsy of the omentum confirmed metastatic carcinoma compatible with the known prostatic primary. He was started on docetaxel with continued luteinizing hormone-releasing hormone (LHRH) therapy, abiraterone, and prednisolone, and remains under oncological surveillance. Conclusion: Peritoneal and omental recurrence can occur after TURP-diagnosed prostate cancer without involvement of the usual sites of spread, and a TURP-related iatrogenic contribution cannot be excluded. A negative PSMA PET/CT does not exclude progression; in selected patients with a marked, sustained PSA rise and new symptoms, repeat imaging may be considered when it is likely to alter management, and histopathological confirmation is required when an atypical metastatic site is suspected.
Fetus in fetu (FIF) is a rare congenital anomaly in which a dysmorphic, parasitic twin is retained within the body of its host twin. It typically presents in infancy, shows a slight male predominance, and is most often located in the retroperitoneum. Differentiating FIF from an abdominal teratoma on imaging is important, as the two entities can closely resemble one another. We report the case of a 10‐year‐old boy who presented with abdominal pain, low‐grade fever, and unintentional weight loss. Antenatal history was unremarkable. Abdominal examination revealed mild distension and left‐sided tenderness. Ultrasonography demonstrated an 8.5 × 10.4 × 11.1 cm mass‐like lesion in the left hypochondrium, and a provisional diagnosis of teratoma versus FIF was considered. Contrast‐enhanced computed tomography (CT) of the abdomen showed a large, well‐defined, heterogeneous mesenteric mass measuring 10.0 × 11.0 × 14.0 cm containing macroscopic fat, dense tooth–like calcifications, and osseous elements with attenuation of up to 1450 Hounsfield units, together with a well‐formed fetal skeleton. Serum tumor markers were within normal limits. A presumptive diagnosis of FIF, supported by imaging and by intraoperative findings that satisfied the Willis criteria, was made at exploratory laparotomy; histopathological confirmation could not be obtained because the specimen was inadequately fixed prior to processing, so a highly differentiated fetiform teratoma cannot be entirely excluded. The child remained well at last follow‐up, about 10 weeks after discharge; longer surveillance is required. This case illustrates that FIF, although classically a diagnosis of infancy, should remain in the differential diagnosis of a complex abdominal mass in an older child, and highlights the role of the Willis criteria, radiological correlation, and intraoperative findings when histopathology is unavailable.
We report a 21‐year‐old male with a giant 20 × 20 × 15‐cm chylous mesenteric cyst. Such cysts present nonspecifically and pose diagnostic and surgical challenges. When a cyst is intimately attached to bowel and shares its mesenteric vascular supply, segmental bowel resection with complete cyst removal may be necessary because safe separation is not possible.